Albiruni R Abdul Razak

Albiruni R Abdul Razak

UNVERIFIED PROFILE

Are you Albiruni R Abdul Razak?   Register this Author

Register author
Albiruni R Abdul Razak

Albiruni R Abdul Razak

Publications by authors named "Albiruni R Abdul Razak"

Are you Albiruni R Abdul Razak?   Register this Author

23Publications

963Reads

7Profile Views

Pretreatment neurocognitive function and self-reported symptoms in patients with newly diagnosed head and neck cancer compared with noncancer cohort.

Head Neck 2018 09 17;40(9):2029-2042. Epub 2018 Apr 17.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.25198DOI Listing
September 2018

Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma.

Cancer Immunol Res 2018 09 17;6(9):1001-1007. Epub 2018 Jul 17.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.

View Article

Download full-text PDF

Source
http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/
Publisher Site
http://dx.doi.org/10.1158/2326-6066.CIR-18-0037DOI Listing
September 2018

Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) - A systematic review and meta-analysis.

Cancer Treat Rev 2018 Feb 6;63:71-78. Epub 2017 Dec 6.

Princess Margaret Cancer Centre, Toronto, Canada; Department of Medicine, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.12.003DOI Listing
February 2018

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

J Clin Oncol 2017 Dec 5;35(34):3851-3858. Epub 2017 Jul 5.

Hans J. Hammers, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; David F. McDermott, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA; Lionel D. Lewis, The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, NH; Martin H. Voss, Memorial Sloan Kettering Cancer Center, New York, NY; Padmanee Sharma, MD Anderson Cancer Center, University of Texas, Houston, TX; Sumanta K. Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Albiruni R. Abdul Razak, Princess Margaret Cancer Centre, Toronto, Ontario; Christian Kollmannsberger, British Columbia Cancer Agency, Vancouver, British Columbia; Daniel Y.C. Heng, Tom Baker Cancer Center, University of Calgary, Calgary; Jennifer Spratlin, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada; M. Brent McHenry, Bristol-Myers Squibb, Princeton, NJ; and Asim Amin, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.72.1985
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.72.1985DOI Listing
December 2017

Survival outcomes for cutaneous angiosarcoma of the scalp versus face.

Head Neck 2017 06 11;39(6):1205-1211. Epub 2017 Apr 11.

Department of Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.24747DOI Listing
June 2017

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.

J Clin Oncol 2016 12 31;34(34):4142-4150. Epub 2016 Oct 31.

Albiruni R. Abdul Razak and Lee-Anne Stayner, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Morten Mau-Soerensen and Ulrik Lassen, Rigshospitalet, Copenhagen, Denmark; Nashat Y. Gabrail, Gabrail Cancer Institute, Canton, OH; John F. Gerecitano, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, NY; Anthony F. Shields, Karmanos Cancer Institute, Wayne State University, Detroit, MI; Thaddeus J. Unger, Jean R. Saint-Martin, Robert Carlson, Yosef Landesman, Dilara McCauley, Tami Rashal, Mansoor R. Mirza, Michael Kauffman, and Sharon Shacham, Karyopharm Therapeutics, Newton, MA; and Richard Kim and Amit Mahipal, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.3949DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562433PMC
December 2016

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

J Clin Oncol 2016 12 31;34(36):4371-4380. Epub 2016 Oct 31.

Suzanne Leijen, Robin M.J.M. van Geel, and Jan H.M. Schellens, The Netherlands Cancer Institute, Amsterdam; Jan H.M. Schellens, Utrecht University, Utrecht, the Netherlands; Anna C. Pavlick, New York University Medical Center, New York, NY; Lee Rosen, University of California Los Angeles, Santa Monica, CA; Raymond Lam, Shelonitda Rose, Mark A. Lee, Tomoko Freshwater, and Stuart Shumway, Merck, Kenilworth, NJ; Geoffrey I. Shapiro, Dana-Farber Cancer Institute, Boston, MA; Albiruni R. Abdul Razak and Amit M. Oza, Princess Margaret Hospital, Toronto, Ontario, Canada; Raoul Tibes, University Hospital of Würzburg, Würzburg; Tim Demuth, Sandoz AG, Holzkirchen, Germany; and Li Wen Liang, Merck Sharp & Dohme R&D, Beijing, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.5991DOI Listing
December 2016

Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT).

Invest New Drugs 2015 Aug 5;33(4):895-900. Epub 2015 May 5.

Department of Medical Oncology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, Canada, M5G 2M9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-015-0245-3DOI Listing
August 2015

Early phase clinical trials to identify optimal dosing and safety.

Mol Oncol 2015 May 14;9(5):997-1007. Epub 2014 Aug 14.

Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.07.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329110PMC
May 2015

Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy.

Cancer Discov 2014 May 17;4(5):527-37. Epub 2014 Apr 17.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-1005DOI Listing
May 2014

Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials.

J Clin Oncol 2013 Nov 14;31(33):4260-7. Epub 2013 Oct 14.

Arif Manji, Irene Brana, Eitan Amir, Ian F. Tannock, Philippe L. Bedard, Amit Oza, Lillian L. Siu, and Albiruni R. Abdul Razak, Princess Margaret Cancer Centre, University Health Network; George Tomlinson, University of Toronto; and Arif Manji, Hospital for Sick Children, Toronto, and Southlake Regional Health Centre, Newmarket, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.4957DOI Listing
November 2013